...
首页> 外文期刊>Journal of Medicinal Chemistry >Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity
【24h】

Novel 4-(4-Aryl)cyclohexyl-1-(2-pyridyl)piperazines as Delta(8)-Delta(7) Sterol Isomerase (Emopamil Binding Protein) Selective Ligands with Antiproliferative Activity

机译:新型4-(4-芳基)环己基-1-(2-吡啶基)哌嗪类化合物具有抗增殖活性的Delta(8)-Delta(7)甾醇异构酶(Emopamil结合蛋白)选择性配体

获取原文
获取原文并翻译 | 示例

摘要

To find Delta(8)-Delta(7) sterol isomerase (EBP) selective ligands, various arylpiperazines previously studied and structurally related to some a receptors ligands were preliminarily screened. Consequently, a novel series of 2- or 2,6-disubstituted (CH3, CH3O, Cl, F) cis- and trans-4-(4-aryl)cyclohexyl-1-(2-pyridyl)piperazines was developed. Radioreceptor binding assays evidenced cis-19, cis-30 and cis-33 as new ligands with nanomolar affinity toward EBP site and a good selectivity relative to EBP-related a receptors. The most selective 2,6-dimethoxy derivative (cis-33) demonstrated the highest potency (EC50 = 12.9 mu M) and efficacy (70%) in inhibiting proliferation of human prostate cancer PC-3 cell line. Among the reference compounds, sigma(2) agonist 36 (PB28) reached the maximum efficacy (100%), suggesting the contribution of the sigma(2) receptor to the antiproliferative activity, This novel class of EBP inhibitors represents a valuable tool for investigating the last steps of cholesterol biosynthesis and related pathologies, as well its a starting point for developing new anticancer drugs.
机译:为了找到Delta(8)-Delta(7)甾醇异构酶(EBP)选择性配体,预先筛选了各种先前研究过并与某些a受体配体结构相关的芳基哌嗪。因此,开发了一系列新颖的2-或2,6-二取代的(CH3,CH3O,Cl,F)顺式和反式-4-(4-芳基)环己基-1-(2-吡啶基)哌嗪。放射性受体结合试验证明了顺式19,顺式30和顺式33是新的配体,对EBP位点具有纳摩尔摩尔亲和力,相对于EBP相关的a受体具有良好的选择性。选择性最高的2,6-二甲氧基衍生物(cis-33)在抑制人前列腺癌PC-3细胞增殖方面显示出最高的效能(EC50 = 12.9μM)和功效(70%)。在参考化合物中,sigma(2)激动剂36(PB28)达到最大功效(100%),表明sigma(2)受体对抗增殖活性的贡献。这一新型的EBP抑制剂代表了一种有价值的研究工具胆固醇生物合成的最后步骤和相关病理,以及开发新的抗癌药物的起点。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号